Estrella Immunopharma, Inc. (ESLA) analyst actions
Rating and price-target actions on ESLA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ESLA overview →
3 measured ESLA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas | Press release | +0.00% | +5.16% | |
| Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners | Press release | — | +1.96% | |
| Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital | Press release | -4.22% | +4.93% |
Keep exploring
More ESLA: earnings → · SEC filings → · ESLA overview →